TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1

PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury

(2018) Karen De Ceunynck et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Demeanor of rivaroxaban in activated/inactivated FXa

(2017) Kaname Seki et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation

(2016) Mohak V. Mhatre et al.   AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran

(2016) Peter Ellinghaus et al.   THROMBOSIS RESEARCH

Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome

(2014) Eric R. Bates et al.   THROMBOSIS AND HAEMOSTASIS

Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug

(2013) Hee Dong Park et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells

(2013) E. M. Gleeson et al.   HAEMATOLOGICA

Antithrombotic and Anticoagulant Profiles of TAK-442, a Novel Factor Xa Inhibitor, in a Rabbit Model of Venous Thrombosis

(2010) Masaki Kawamura et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Discovery of a Tetrahydropyrimidin-2(1H)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor

(2010) Takuya Fujimoto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding

(2010) Noriko Konishi et al.   THROMBOSIS AND HAEMOSTASIS

Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity

(2008) Samuel Chackalamannil et al.   JOURNAL OF MEDICINAL CHEMISTRY